Asmus M J, Milavetz G, Tice A L, Teresi M E
College of Pharmacy, University of Florida, Gainsville, USA.
Pharmacotherapy. 2001 May;21(5):534-9. doi: 10.1592/phco.21.6.534.34547.
To compare the in vitro performance of an ultrasonic nebulizer and a jet nebulizer in producing a respirable aerosol of tobramycin solution for injection.
In vitro observational study
Ultrasonic and jet nebulizers.
Output was determined by measuring the difference in nebulizer weight before and after nebulizing 3 ml of tobramycin injection solution. Mass median aerodynamic diameter (MMAD) and respirable mass were determined by sampling tobramycin aerosol into a cascade impactor.
Mean (SD) output was 1.14 (0.09) ml/minute for the ultrasonic nebulizer and 0.64 (0.08) ml/minute (p<0.001) for the jet nebulizer. Mean MMAD for the jet nebulizer (2.31 [0.10] microm) was less than that of the ultrasonic nebulizer (2.81 [0.17] microm, p<0.001). The majority of tobramycin aerosol produced was in the respirable range for both the ultrasonic (65.1% [4.10%]) and jet (60.6% [0.73%], p=0.008) nebulizers.
Despite small, clinically unimportant differences in aerosol size and respirable fraction, either device would be acceptable to administer tobramycin injection solution.
比较超声雾化器和喷射雾化器在制备可吸入性注射用妥布霉素溶液气雾剂方面的体外性能。
体外观察性研究
超声雾化器和喷射雾化器。
通过测量雾化3毫升妥布霉素注射液前后雾化器重量的差异来确定输出量。通过将妥布霉素气雾剂采样到多级冲击器中来测定质量中值空气动力学直径（MMAD）和可吸入质量。
超声雾化器的平均（标准差）输出量为1.14（0.09）毫升/分钟，喷射雾化器为0.64（0.08）毫升/分钟（p<0.001）。喷射雾化器的平均MMAD（2.31 [0.10]微米）小于超声雾化器（2.81 [0.17]微米，p<0.001）。超声雾化器（65.1% [4.10%]）和喷射雾化器（60.6% [0.73%]，p = 0.008）产生的大部分妥布霉素气雾剂都在可吸入范围内。
尽管气雾剂大小和可吸入分数存在微小的、临床上不重要的差异，但两种设备均可用于给药妥布霉素注射液。
Zotero 插件